PACT-2022-cohort---header

PACT Advocacy Academy graduates first cohort

The World Federation of Hemophilia (WFH) Path to Access to Care and Treatment (PACT) Program is a 5-year initiative designed to improve outreach and diagnosis and increase access to sustainable care for people with inherited bleeding disorders. In 2022, the WFH launched the PACT Advocacy Academy, which provides NMO leaders and patient advocates with the necessary knowledge and skills to carry out successful evidence-based advocacy campaigns. Last year, the academy graduated its first cohort of 23 people from 18 countries.

Also available in: Français Español

Over a period of eight months, PACT Advocacy Academy participants completed four modules co-created by the WFH and New York University – Robert F. Wagner Graduate School of Public Service. The modules covered key concepts in bleeding disorders, principles of care, and advocacy; advocacy skills and campaign design; introduction to health economics and health technology assessments; and key concepts in therapeutic products, procurement models, and tenders. Participants also developed real-life advocacy campaigns through a series of practical assignments. The instructors and mentors, who included advocacy and bleeding disorders experts, trained and advised the students through the lens of advocating for safe and sustainable treatment and care—a key strategic objective of the WFH.

Participants showed a marked increase in knowledge after completing the self-directed sessions.

The feedback from participants was overwhelmingly positive, with the majority stating that their experience gave them the tools they needed to advocate more effectively in the real world. Juan Andrés Pereira de Souza from Uruguay shared with us that what he learned during his time in the PACT Advocacy Academy reinforced and expanded his knowledge of advocacy strategies, and gave him the skills to organize advocacy projects more effectively. Agnes Kisakye from Uganda said she felt that her experience helped her become more equipped to engage with stakeholders in policy and advocacy, and helped her gain a more comprehensive and patient-centered approach to program interventions.

I was happy to share my learnings from the PACT Advocacy Academy with the Hemophilia Philippines Foundation… my team will now put into practice the concepts and skills I have learned to advance our lobbying efforts with the Philippine Health Insurance Corporation (PhilHealth), local governments, and the National Institute of Health. The program helped me and my organization refocus and reorganize our initiatives for the Philippine hemophilia community.

—Flerida Hernandez from the Philippines

In 2023, the WFH will build on the successes of the program’s first year, notably by expanding to offer courses in three languages: English, French, and Spanish. The new cohort has already begun their instruction, and the enthusiasm among participants is high. During the orientation session in January, Cesar Garrido, WFH President, reminded the participants to always be strategic in their work, so that together, they can work towards our shared vision of Treatment for All.

To find out more about the WFH Path to Access to Care and Treatment (PACT) Program, please click here.

The PACT (Path to Access to Care and Treatment) Program is supported by funding from Roche, our visionary partner; CSL Behring, Pfizer and Sanofi Genzyme, our leadership partners; and Bayer, Biotest and Grifols, our collaborating partners. 

We’ve accomplished a lot this year, we need your help to continue strong.

Would you like to read more about similar articles?

Disclaimer

The information on the WFH website is provided for general information purposes only. The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

While every effort has been made to ensure the accuracy of the information on this site, the WFH does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.

Messages posted to WFH discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.

References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH. The WFH is not responsible and assumes no liability for the content of any linked websites.

Fraud Alert

Unauthorized solicitations – Warning

The WFH has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH staff or falsely stating that they are associated with the WFH. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH, are fraudulent and come from outside of our organization.

If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH emails come from @wfh.org).

We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH at [email protected] or call +1 514-875-7944.